Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifolates: the next generation.

G F Fleming1, R L Schilsky

  • 1Department of Medicine, University of Chicago, IL 60637.

Seminars in Oncology
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

ESMO open·2025
Same author

Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Nature·2019
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

New antifolates, designed to overcome methotrexate resistance, show promise in clinical trials. These agents offer expanded therapeutic potential in cancer, infections, and autoimmune diseases.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Development

Background:

  • Methotrexate resistance is a significant challenge in cancer chemotherapy.
  • Understanding folate metabolism and transport is key to designing new antifolates.
  • Existing antifolates face limitations due to resistance mechanisms.

Purpose of the Study:

  • To review promising new antifolate agents in clinical trials.
  • To discuss their rational design based on resistance mechanisms.
  • To explore their potential applications beyond cancer therapy.

Main Methods:

  • Review of clinical trial data for novel antifolates.
  • Analysis of drug design strategies targeting folate pathways.
  • Comparison of new agents with methotrexate.

Related Experiment Videos

Main Results:

  • Several new antifolates demonstrate efficacy against methotrexate-resistant cell lines.
  • Agents differ in properties like lipid solubility and polyglutamation.
  • Some target folate-dependent enzymes beyond dihydrofolate reductase.

Conclusions:

  • New antifolates represent a significant advancement in chemotherapy.
  • These agents offer potential for treating cancers, infections, and rheumatic diseases.
  • Further clinical evaluation is warranted to establish their full therapeutic value.